Host: Jay D. Raman, MD, FACS
Co-Host: Michael S. Cookson, MD, MMHC
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Interpret the evidence and outcomes on the treatment of M0 HSPC, M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced Prostate Cancer Guideline encompassing metastatic HSPC and CRPC disease.
2. Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice.
ACKNOWLEDGEMENTS:
This series is supported by independent educational grants from:
- Astellas
- AstraZeneca
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi Genzyme